image

The best stocks to buy since 1993

Latest issue now available

Creo

July 2023

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • CREO
  • Price:
  • 35p
The shares broke decidedly higher. In recent weeks Creo has successfully completed the first human use of its MicroBlate Flex at the Royal Brompton Hospital, London (clinical study NCT05786625) to demonstrate the safety and efficacy of the device for the microwave ablation of lung lesions, accessed minimally invasively via a bronchoscope. Headline data could be available by H1 24, which will support the commercial launch of the device. Separately, its Speedboat Inject device has been selected for assessment by NICE which, if favourable, would support increased adoption of the device in the UK. This month the device received clearance for the whole gastrointestinal (GI) tract whereas before it was only cleared for use in lower GI i ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author

LIMITED PERIOD OFFER!

SUBSCRIBE TODAY AND SAVE £30 WITH OFFER CODE 30OFFSCSW

To access our archive of articles and to receive current issues you need to subscribe